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ABSTRACT  
Cytosolic delivery remains a major bottleneck for siRNA therapeutics. To facilitate delivery, siRNAs 
are often enclosed in nanoparticles (NPs). However, upon endocytosis such NPs are mainly trafficked 
toward lysosomes. To avoid degradation, cytosolic release of siRNA should occur prior to fusion of 
endosomes with lysosomes, but current endosomal escape strategies remain inefficient. In contrast to 
this paradigm, we aim to exploit lysosomal accumulation by treating NP-transfected cells with low 
molecular weight drugs that release the siRNA from the lysosomes into the cytosol. We show that 
FDA-approved cationic amphiphilic drugs (CADs) significantly improved gene silencing by siRNA-
loaded nanogels in cancer cells through simple sequential incubation. CADs induced lysosomal 
phospholipidosis, leading to transient lysosomal membrane permeabilization and improved siRNA 
release without cytotoxicity. Of note, the lysosomes could be applied as an intracellular depot for 
triggered siRNA release by multiple CAD treatments. 
 
Keywords: drug repurposing, siRNA delivery, nanogels, phospholipidosis, lysosomal membrane 
permeabilization, cationic amphiphilic drugs 
 
GRAPHICAL ABSTRACT 
 
Through functional inhibition of acid sphingomyelinase (ASM), cationic amphiphilic drugs (CADs) 
induce non-lethal lysosomal membrane permeabilization (LMP), enhancing the cytosolic delivery of 
siRNA and improving target gene knockdown.  
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1. INTRODUCTION 
The cytosolic delivery of RNA interference (RNAi)-effectors, such as small interfering (si)RNA, 
efficiently and specifically induces post-transcriptional gene silencing [1, 2]. In theory any gene of 
interest can be targeted, making siRNAs promising therapeutic candidates for a myriad of diseases 
[3, 4]. Since their negative charge and relatively high molecular weight hinder passive diffusion over 
the cell membrane, siRNA is generally enclosed in a nanocarrier to ensure cellular uptake [5]. Such 
carriers are internalized by cells via one or more endocytic pathways but are progressively trafficked 
to the lysosomes, where both particle and cargo face degradation. However, as cytosolic siRNA 
delivery is needed to activate the RNAi pathway and reduce gene expression, lysosomal entrapment 
is generally regarded as a non-functional dead end [5]. To avoid lysosomal degradation, endosomal 
escape should occur prior to fusion of the endosomes with the lysosomes [6, 7]. Unfortunately, the 
rapid trafficking towards the lysosomes strongly limits the time-window to induce release [8]. In 
addition, it is believed that endosomal escape strategies should target early or late endosomes since 
the induction of severe lysosomal membrane damage may trigger cell death, e.g. through leakage of 
lysosomal cathepsins [6, 9]. Despite many efforts to improve endosomal escape through optimal 
nanoparticle (NP) design, state-of-the-art siRNA NPs largely fail to deliver, as the bulk of the 
internalized siRNA dose remains entrapped in the lysosomes [10, 11]. Opposed to the current 
paradigm, we propose to specifically exploit the lysosomes for cytosolic siRNA delivery by 
repurposing cationic amphiphilic drugs (CADs) as low molecular weight adjuvants. CADs are 
pharmacologically diverse compounds that preferentially accumulate in lysosomes given their 
amphiphilic and weak basic properties [12]. CADs are able to passively diffuse into the acidified 
lysosomal lumen where they are protonated upon which their re-diffusion into the cytosol is hindered, 
a phenomenon referred to as ‘ion-trapping’ [12, 13]. Here, protonated CADs insert in intra-lysosomal 
membranes with their hydrophobic segment, causing the detachment of the membrane-associated 
acid sphingomyelinase (ASM) and its subsequent degradation by cathepsins in the lysosomal lumen 
(Figure 1) [14].  
Thus, many CADs are known as functional inhibitors of ASM (FIASMAs) [12, 15]. ASM catalyzes the 
hydrolysis of sphingomyelin (SM) to ceramide, thereby playing an important role in the maintenance 
of the lipid homeostasis and lysosomal membrane integrity. Indeed, SM accumulation upon ASM 
inhibition is associated with induction of lysosomal membrane permeabilization (LMP) in cancer cells 
(Figure 1) [14, 16, 17]. Here, we aimed to evaluate if this phenomenon can be exploited to improve 
cytosolic siRNA delivery following NP-mediated transfection.  
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Figure 1. CAD-mediated functional ASM inhibition causes lysosomal lipid accumulation and 
lysosomal membrane permeabilization. (a) Acid sphingomyelinase (ASM) is a lysosomal 
membrane-bound enzyme that contributes to lipid metabolism. At the acidic pH of the lysosomes, the 
cationic ASM is electrostatically bound to intraluminal vesicles (ILVs) that are enriched in the anionic 
lipid bis(monoacylglycero)phosphate (BMP). (b) Cationic amphiphilic drugs (CADs) preferentially 
accumulate in lysosomes given their amphiphilic and weak basic properties. (c) Protonated CADs 
insert in intra-lysosomal membranes and (d) induce ASM release into the lysosomal lumen (e) 
followed by degradation by cathepsins. As a result, lysosomal (phospho)lipidosis develops, 
accompanied by lysosomal swelling and (f) lysosomal membrane permeabilization (LMP) [14, 18]. 
 
2. MATERIAL AND METHODS 
2.1. siRNA duplexes 
The 21 nucleotide siRNA duplex targeting the enhanced green fluorescent protein (eGFP; siEGFP) 
and the control siRNA duplex (siCTRL) were purchased from Eurogentec (Belgium). This control 
duplex contains a unique and validated sequence that does not present any relevant homology to any 
known eukaryotic gene. For uptake experiments, the siCTRL duplex was labeled with a Cy5 dye at 
the 5´ end of the sense strand (Eurogentec, Belgium). Nuclease-stabilized versions of the siEGFP 
and siCTRL duplexes (siSTABLE), the siGLO green transfection indicator as well as nuclease-
stabilized siRNA targeting polo-like kinase 1 (siPLK1) were obtained from Dharmacon (USA). The 
sequences and modifications of the applied siRNA duplexes are summarized in Table 1. 
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Table 1. Applied siRNA sequences and duplex modifications. 
siRNA Modification Manufacturer 
Sequencea 
Sense strand (5’ -> 3’) Antisense strand (5’ -> 3’) 
siCTRLb / Eurogentec UGCGCUACGAUCGACGAUGtt CAUCGUCGAUCGUAGCGCAtt 
siCTRLb Cy5-labeledc Eurogentec UGCGCUACGAUCGACGAUGtt CAUCGUCGAUCGUAGCGCAtt 
siCTRLb Stabilizedd Dharmacon UAGCGACUAAACACAUCAAUU UUGAUGUGUUUAGUCGCUAUU 
siEGFPe / Eurogentec CAAGCUGACCCUGAAGUUCtt GAACUUCAGGGUCAGCUUGtt 
siEGFPe Stabilizedd Dharmacon 
CAAGCUGACCCUGAAGUUCU
U 
GAACUUCAGGGUCAGCUUGUU 
siGLO FAM-labeledf Dharmacon Not provided Not provided 
siPLK1g Stabilizedd Dharmacon CAACCAAAGUCGAAUAUGAUU UCAUAUUCGACUUUGGUUGUU 
a Capital and lower case letters respectively represent ribonucleotides and 2′-deoxyribonucleotides; b negative 
control duplex; c the siCTRL duplex was labeled with a Cy5 dye at the 5´ end of the sense strand; d siSTABLE 
modification (Dharmacon); e siRNA duplex targeting enhanced green fluorescent protein; fsiGLO green 
transfection indicator (Dharmacon);  g siRNA duplex targeting polo-like kinase 1 
2.2. NG complexation 
The cationic dextran nanogels (NGs) were prepared via an inverse mini-emulsion 
photopolymerization method [19]. For siRNA loading, a 2 mg/mL dispersion of a lyophilized NG stock 
was prepared in ice-cooled nuclease free water and sonicated briefly (amplitude 10%). Subsequently, 
equal volumes of appropriate NG and siRNA dilutions in N-2-hydroxyethylpiperazine-N′-2-
ethanesulfonic acid (HEPES) buffer (pH 7.4, 20 mM) were mixed to a final volume of 100 µL and were 
allowed to complex for 15 minutes at room temperature. The siRNA loaded NGs (siNGs) were 
subsequently diluted with HEPES (100 µL) and Opti-MEM® (Invitrogen, Belgium, 800 µL) to a final 
volume of 1 mL. This complexation procedure was applied for all cell-based experiments and resulted 
in a 30 µg/mL NG dispersion loaded with 2 nM siRNA (= 0.067 pmol siRNA/µg NGs or 0.6 pmol 
siRNA/well). 
2.3. Cell lines and cell culture conditions 
Non-small cell lung carcinoma cells (H1299), both the wild type (H1299-WT) and the eGFP-
expressing variant (H1299-eGFP), were maintained in RPMI 1640 culture medium supplemented with 
10% fetal bovine serum (FBS, HycloneTM, Thermo Fisher Scientific, Belgium), 2 mM L-Glutamine and 
100 U/mL penicillin/streptomycin. The cell lines were cultured in a humidified atmosphere containing 
5% CO2 at 37 °C and culture medium was renewed every other day unless the 80% confluence level 
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was reached. In this case, the cells were split using 0.25% trypsin-EDTA. All products were 
purchased from Invitrogen (Belgium) unless specifically mentioned otherwise. 
2.4. siNG transfection and sequential adjuvant treatment 
Cells were transfected with siNGs during 4 hours at 37 °C in a humidified atmosphere containing 5% 
CO2. Subsequently, the siNG dispersion was removed, the cells were washed once with phosphate 
buffered saline (PBS, Invitrogen, Belgium) and received fresh cell medium. In case of CAD treatment, 
complete cell medium containing the CAD or combination of CADs at the indicated concentrations 
was applied on the cells for 20 hours, unless specifically mentioned otherwise. Four different CADs 
were tested, namely carvedilol (CD), desloratadine (DL), nortriptyline (NT) and salmeterol (ST) (Figure 
2). In additional experiments, we applied complete cell medium containing 10, 20 or 40 µM 
chloroquine (CLQ), 30 µM U18666A or 300 µM 2-hydroxy oleic acid (2OHOA), the latter either alone 
or in combination with 10 µM DL. Figure S2 shows the molecular structure, logP and pKa values of 
the additionally applied endosomolytic adjuvants. All small molecules were obtained from Sigma-
Aldrich (Belgium) and the stock solutions were prepared in sterile-filtered BioPerformance Certified 
dimethyl sulfoxide (DMSO, Sigma-Aldrich, Belgium). The final DMSO concentration on the cells did 
not exceed 0.16 vol%. Following adjuvant incubation, the small molecule-containing cell medium was 
removed and cells were kept in 1 mL fresh cell medium for an additional 24 hours until analysis. It 
was verified that the solvent in which the CADs were dissolved (DMSO) did not influence the siNG-
mediated gene silencing (data not shown). 
2.5. Quantification of the siNG transfection efficiency 
For silencing experiments, H1299-eGFP cells were seeded in 24 well plates at a density of 35000 
cells/well and were allowed to settle overnight. Subsequently, the cells were transfected with 0.6 pmol 
siRNA/well (4 hours incubation, 300 µL siNG dispersion) and treated with 0.5 mL cell medium 
containing a small molecular adjuvant (20 hours incubation unless specifically stated otherwise). Note 
that for every siEGFP or siPLK1 condition an siCTRL sample was included to account for potential 
off-target effects. SiNG-mediated eGFP silencing was quantified by flow cytometry. Sample 
preparation consisted of washing the cells with PBS, followed by detachment with 0.25% trypsin-
EDTA. Next, the cells were collected, centrifuged 5 minutes at 300 g, resuspended in 300 µL flow 
buffer (1% FBS in PBS) and kept on ice until analysis. For each sample the forward and side scatter 
as well as the green fluorescent signal were acquired for at least 15000 cells. The samples were 
excited with the 488 nm laser line and the signal was detected with the 530/30 filter using the 
FACSCalibur™ flow cytometer (BD Biosciences, Belgium) and BD CellQuest™ acquisition software. 
Finally, data analysis was performed using the FlowJo software (Tree Star Inc.) and the calculated 
percentage eGFP expression is presented as the mean ± standard error of the mean (SEM) for 4 
independent repeats. When probing the kinetics of the eGFP expression over an extended period of 
time, the eGFP signal was measured daily. Hereto, treated cells were passaged every other day and 
reseeded in new 24 well plates during sample preparation for the flow cytometry measurements. The 
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silencing potential of the siPLK1-loaded NGs was established through evaluating the cell viability with 
the CellTiter GLO® assay (Promega, Belgium). Before initiating the assay, the culture plates and 
reconstituted assay buffer were placed at room temperature for 30 minutes. Next, the culture medium 
was replaced by 250 µL fresh cell medium and an equal volume of assay buffer was added. To 
induce complete cell lysis, the plates were shaken during 2 minutes and the signal was allowed to 
stabilize the following 10 minutes. 100 µL from each well was subsequently transferred to an opaque 
96-well plate, which was measured with a GloMax® 96 Microplate Luminometer (Promega, Belgium). 
Three independent repeats were performed and data are expressed as the mean cell viability (%) ± 
SEM. 
2.6. Cell viability 
The H1299-eGFP cells were seeded, transfected with siCTRL-loaded NGs and treated with the CADs 
similar to the silencing experiments. Again, the CellTiter GLO® assay was performed as described 
above in 3 independent repeats (data are expressed as the mean ± SEM). 
2.7. Cellular release of FITC-dextrans and Cy5-oligonucleotides 
H1299-WT cells were seeded at 105000 cells/dish in 35 mm diameter glass bottom microscopy 
dishes (Greiner Bio-One GmbH, Germany) and were allowed to settle overnight. To visualize the 
FITC-dextran (FD) release from lysosomes, a 1 mg/mL dispersion of 10 kDa FD (Sigma-Aldrich, 
Belgium) in complete cell medium was added during 1 hour at 37 °C in a humidified atmosphere 
containing 5% CO2. Fluorescently labeled dextrans (10 kDa) are internalized by cells through fluid-
phase pinocytosis and are useful probes to assess lysosomal integrity [20, 21]. To assess 
oligonucleotide (ON) escape, the NGs were first loaded with 100 nM Alexa Fluor 647-labelled ON 
(Eurogentec, Belgium) according to the procedure described for siRNA complexation and 900 µL of 
the ON-loaded NG dispersion was added to each dish. Following 4 hours of ON-loaded NG 
transfection or 1 hour incubation with FD, the cells were washed with PBS and received 1.5 mL fresh 
cell medium with or without 10, 20 or 40 µM DL. After an additional incubation period of 20 hours, the 
cell medium was removed and nuclei were labeled with Hoechst (Molecular ProbesTM, Belgium) in cell 
medium during 15 minutes at 37 °C. Finally, the Hoechst solution was removed, fresh cell medium 
was added and cells were kept at 37 °C in a humidified atmosphere containing 5% CO2 until imaging 
using a laser scanning confocal microscope (LSCM, C1si, Nikon) and a 60x oil immersion Plan Apo 
objective (Nikon, Belgium). The 408 nm, 488 nm and 633 nm laser lines were applied to respectively 
excite the Hoechst labeled nuclei, the FD and ON. During data analysis with ImageJ, both the total 
cell number and number of cells with a diffuse FD labeling or ON-positive nuclei were counted. Data 
are represented as the percentage of cells with a diffuse FD signal for minimum 225 cells per 
condition in 10 images and the percentage of cells with ON-positive nuclei for at least 180 cells in 10 
images. FD- or ON-treated cells not exposed to DL were employed as the negative control. 
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2.8. Quantification of lysosomal volume using flow cytometry 
H1299-eGFP cells were seeded, transfected and treated with the CADs as described for the cell 
viability experiments. Following 20 hours of CAD treatment, the lysosomes were labeled with the 
LysoTracker® Deep Red (LDR) probe (Molecular Probes™, Belgium) through incubation with 1 mL 
75 nM LDR in cell medium for 30 minutes at 37 °C. Further sample preparations were carried out as 
previously described for the silencing experiments. Using the FACSCalibur™ flow cytometer and BD 
CellQuest™ acquisition software, the LDR signal was detected with the 661/16 filter following 
excitation with the 635 nm laser line for at least 15000 cells per sample. Experiments were performed 
in biological triplicate and fold changes in LDR signal intensity are expressed as the mean ± SEM. 
2.9. Visualizing lysosomes, phospholipids, cholesterol and sphingomyelin  
H1299-WT cells were seeded as specified for the FD release experiment and transfected with siNGs 
followed by a 20 hour DL treatment. Subsequently, lysosomes were labeled with LysoTracker® Red 
DND-99 (Molecular Probes™, Belgium). Phospholipids were stained with the LipidTOX™ red 
phospholipidosis detection reagent (Thermo Fisher Scientific, USA). Cholesterol could be detected 
following labeling with filipin. Finally, lysenin (Sigma-Aldrich, Belgium) was applied to label 
sphingomyelin. Detailed labeling, imaging and analysis procedures are provided in the supporting 
information.  
2.10. Transfection with siGLO green transfection indicator 
H1299-WT cells were seeded as described previously. For this experiment, NGs were complexed with 
100 nM green fluorescent siRNA (siGLO, Dharmacon, USA). Following transfection and 40 µM DL 
treatment, the cells were fixed with 4% PFA and stored in Vectashield containing DAPI. The samples 
were imaged with a LSCM and a 100x oil immersion objective following excitation with the 408 nm 
and 488 nm laser line to visualize the DAPI and siGLO signal, respectively. 
2.11. Statistical analysis 
Statistical analysis was performed using the 6th version of the GraphPad Prism software. One-way 
ANOVA combined with the post-hoc Dunnett test was applied to compare multiple conditions, 
whereas the student t-test was used for direct comparison of 2 conditions. 
 
3. RESULTS AND DISCUSSION 
3.1. CAD treatment enhances siRNA-mediated gene silencing of nanogels 
We selected four structurally diverse, FDA-approved CADs with a distinct pharmacological activity, 
namely carvedilol (CD, a β-blocker), desloratadine (DL, an antihistamine), nortriptyline (NT, an 
antidepressant) and salmeterol (ST, a β2-agonist) (Figure 2). All compounds have an estimated logP 
> 3 and pKa > 7.4 and can thus be classified as lysosomotropic drugs, CADs and FIASMAs [12, 15].  
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Figure 2. Applied cationic amphiphilic drugs. The drug class, logP, pKa values and molecular 
structure of carvedilol (CD), desloratadine (DL), nortriptyline (NT) and salmeterol (ST) [22]. 
As a model NP, we applied siRNA-loaded, biodegradable cationic dextran nanogels (siNGs) that have 
demonstrated high uptake and gene silencing efficiency in cancer cells [19, 23]. Here, non-small cell 
lung cancer cells (H1299) that stably express the enhanced green fluorescent protein (eGFP) were 
first transfected with siNGs, loaded with a suboptimal siRNA dose (2 nM or 0.6 pmol siRNA/well). In 
line with earlier observations, the siNGs were efficiently internalized by the H1299 cells (Figure S1A) 
and induced ~25% eGFP silencing under the given experimental conditions (Figure 3A) [19, 23]. 
Notably, a sequential 20 hour treatment with each compound significantly improved the siNG 
silencing potential in a similar concentration-dependent fashion (Figure 3A, Figure S1B), despite the 
marked variation in drug class and molecular structure [22]. Interestingly, combining two different 
CADs allowed additive effects on eGFP knockdown, as shown for DL and NT (Figure 3B), which is in 
line with the reported additive ASM inhibition [12]. Our adjuvant approach furthermore outperformed 
the gold standard for siRNA transfections, i.e. Lipofectamine® RNAiMAX, when used at a similar 
siRNA concentration as the suboptimal siNGs (0.6 pmol siRNA/well) (Figure 3C). Note that, as 
compared to Lipofectamine RNAiMAX, the same level of knockdown can be achieved with a 10-fold 
lower dose of siRNA by sequential CAD addition to siNG-transfected cells. Such a dose sparing 
strategy could strongly reduce the risk of siRNA-related adverse effects. In turn, not all CADs are 
active in the same dose range as 10-fold higher concentrations of dextromethorphan were required to 
obtain a similar adjuvant effect relative to the other CADs tested (Figure 3D). This may be attributed 
to steric hindrance of the basic amine reducing efficient ASM membrane detachment [22, 24]. Finally, 
sequential addition of the well-known endosomal escape enhancer chloroquine (CLQ) equally 
improved siNG-mediated silencing (Figure 3E). However, the use of CLQ as a delivery enhancer is 
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limited by its systemic toxicity, while other CADs, e.g. antihistamines, may provide a safer alternative 
[25]. 
We subsequently evaluated the impact of the CAD treatment, alone or sequential to the siNG 
transfection, on cell viability. Figure 4A-B indicates that the CADs were overall well tolerated in the 
applied concentration range with DL and CD being the least and most cytotoxic, respectively.  
3.2. Desloratadine improves the cytosolic delivery of macromolecules 
We hypothesized that the sequential CAD treatment improved the siNG silencing potential by 
facilitating siRNA release into the cytosol, through the induction of lysosomal membrane 
permeabilization (LMP). To visualize LMP, the H1299 lysosomes were first labeled with FITC-dextran 
(FD, 10 kDa). For dextrans of this molecular weight it is known that upon fluid phase uptake they are 
efficiently trafficked towards the lysosomal compartments, making them ideal probes to monitor 
lysosomal integrity. The cytosolic release of labeled dextrans is a frequently applied method to probe 
LMP [20, 21]. Upon lysosomal leakage of FD due to LMP, the affected cells should show a diffusely 
stained cytosol in contrast to the typical punctate pattern indicative of lysosomal sequestration [20]. 
As expected, the punctate pattern was observed in the bulk of the untreated cells (Figure 4C). Upon 
DL adjuvant treatment, we observed a concentration-dependent increase in the percentage of cells 
with a diffuse FD labeling, reaching up to ~26% with 40 µM DL. Comparable results were obtained by 
applying NGs loaded with negatively charged Cy5-labeled oligonucleotides (Cy5-ON) (data not 
shown) [26]. Although the percentage of positive cells correlates well for both methods, it was lower 
than anticipated based on the eGFP gene silencing results. Indeed, upon cytosolic release of a limited 
amount of FD or Cy5-ON, the labels are diluted in the cell and might fall below the detection limit of a 
standard confocal microscope [11]. 
3.3. The lysosomal compartment is affected by CAD treatment 
Next, we assessed the impact of the CAD treatment on the lysosomes of siNG-transfected cells by 
quantifying the total endo-lysosomal volume with the lysosomotropic dye LysoTracker® Deep Red 
(LDR). Figure 5A-B shows that all four CADs evoked a similar concentration-dependent signal 
increase compared to untreated and siNG transfected cells. These observations could visually be 
confirmed by confocal microscopy, showing a marked enlargement of LysoTracker® Red labeled 
vesicles (Figure 5C), as also reflected in the LysoTracker® Red signal area (Figure 5D). These data 
corroborate earlier findings on lysosomal volume expansion in cells that had been exposed to CADs 
[27]. 
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Figure 3. CADs boost siRNA-mediated gene silencing upon siNG transfection. (A) Sequential 
treatment of siNG-transfected H1299-eGFP cells with CADs during 20 hours improved eGFP 
silencing in a concentration-dependent manner. (B) Combinations of desloratadine (DL) and 
nortriptyline (NT) evoked additive effects on eGFP silencing. (C) Comparison of eGFP knockdown 
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between siNGs and Lipofectamine® RNAiMAX. (D) Impact of sequential addition of dextrometorphan 
(DX) on siNG-mediated eGFP silencing in H1299-eGFP cells. (E) The endosomal escape enhancer 
chloroquine (CLQ) equally improves siNG-mediated gene silencing. Data are represented as mean ± 
SEM for minimum 3 independent repeats (n=3). Statistical significance, with respect to NG 
transfection alone, is indicated when appropriate (* p<0.05, ** p<0.01, *** p<0.005). Statistical 
significance between NG + 40 µM DL and RNAiMAX is indicated when appropriate (xxx p<0.005). 
 
Figure 4. CADs improve macromolecule release to the cytosol while inducing limited 
cytotoxicity levels. Cell viability of H1299-eGFP cells following CAD treatment alone (A) or 
sequential NG transfection and CAD addition (B). Data reflect the mean ± SEM (n=3 independent 
repeats) and statistical significance is indicated when appropriate (* p<0.05, ** p<0.01, *** p<0.005). 
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In (B) the black * represent significant variations relative to the untreated control (NTC), whereas the 
gray * resemble significant differences with respect to the cells transfected with siCTRL-NGs. (C) 
Representative confocal images from the intracellular FITC-dextran (10 kDa) distribution in untreated 
H1299-WT cells or cells incubated with 10, 20 or 40 µM DL following FITC-dextran uptake via 
endocytosis. The values below the images correspond to the percentage of cells with a diffuse FITC-
dextran labeling. The scale bar corresponds to 50 µm. (NTC = not treated control, NG = nanogels, 
CAD = cationic amphiphilic drug, NT = nortriptyline, ST = salmeterol, CD = carvedilol, DL = 
desloratadine) 
Interestingly, this CAD-induced lysosomal swelling furthermore increased the cellular granularity, as 
indicated by the augmented side scatter (SSC) signal (Figure 5E-F, Figure S3A) and the combination 
of CADs resulted in additive SSC increases (Figure S3B). In line with the concentration-dependent 
effect of dextromethorphan on siNG-induced gene silencing (Figure 3D), only doses above 80 µM 
significantly augmented the SSC signal (Figure S3C), although the effect was less outspoken 
compared to the other molecules tested. 
3.4. CADs induce a lysosomal storage disease-like phenotype 
CADs are known lysosomotropic agents and phospholipidosis (PLD) inducers, although the 
underlying cause is still unclear [28]. Labeling CAD-treated cells with the PLD detection reagent 
LipidTOX™ Red (Figure 6A), revealed that DL treatment induced PLD. The lipids accumulated in 
vesicular structures, which enlarged as a function of the DL concentration. Again, only higher doses of 
dextromethorphan (≥80 μM) clearly induced vesicular phospholipid accumulation.  
Such lysosomal swelling due to lipid accumulation is a general phenotypical feature of lysosomal 
storage disorders [29]. CADs are known to induce a Niemann-Pick disease (NPD) phenotype [30]. 
NPD is a lysosomal storage disorder caused by either a depletion of the Niemann-Pick type C1 
(NPC1) protein that is involved in cholesterol transport (NPD type C) or a genetic defect in the ASM 
enzyme (NPD type A). Both NPD type A and C present a similar phenotype that is characterized by 
less stable, enlarged lysosomes due to the accumulation of cholesterol and sphingolipids, including 
SM [24, 31]. Interestingly, sequential treatment of siNG transfected cells with U18666A, a structurally 
different low molecular weight NPD inducer (Figure S2), also markedly increased cellular granularity 
(Figure 6B) as well as siNG-mediated gene silencing (Figure 6C).  
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Figure 5. CADs affect the lysosomal compartment. Fold change in LDR signal measured via flow 
cytometry for H1299-eGFP cells treated only with the CADs (A) or the combination of siNGs and 
CADs (B). (C) Representative confocal images showing the lysosomal compartment (red) following 
LysoTracker® Red labeling for untreated H1299-WT cells, NG-transfected cells or cells transfected 
with siNGs followed by 10, 20 or 40 µM DL treatment. (D) Fold increase in signal area relative to the 
untreated control quantified from the confocal images in (C). (E) Fold change in side scatter induced 
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by NG transfection or sequential treatment with DL. (F) Representative scatter plots for untreated 
cells, NG-transfected cells or cells transfected with siNGs followed by 10, 20 or 40 µM DL treatment. 
Data are represented as the mean ± SEM (n=3) and statistical significance is indicated when 
appropriate, in black when referring to the untreated control and in gray when compared to NG 
transfected cells (* p<0.05, ** p<0.01, *** p<0.005). (NTC = not treated control, LDR = LysoTracker® 
Deep Red, CAD = cationic amphiphilic drug, NG = nanogels, NT = nortriptyline, ST = salmeterol, CD 
= carvedilol, DL = desloratadine, FSC = forward scatter, SSC = side scatter) 
In line with our results on lysosomal swelling (Figure 5C) and phospholipid accumulation, we 
observed vesicular accumulation of cholesterol and SM upon CAD treatment (Figure 6D-E, Figure 
S4), further supporting the notion that CADs reduce ASM activity and induce a NPD phenotype. The 
additive effect of 2-hydroxy oleic acid (2-OHOA), a known activator of the SM synthase, and DL on 
the siRNA-mediated gene silencing indeed suggests an involvement of the disturbed SM homeostasis 
in the improved cytosolic siRNA delivery (Figure 6F) [32]. Of note, recent literature reports have 
shown enhanced siRNA delivery in NPC1-/- cells and upon NPC1 inhibition by NP3.47, a putative 
inhibitor of the NPC1 protein that was initially discovered in a compound screen to identify blockers of 
Ebola viral infection. These results were however explained by reduced exocytosis of the lipid-based 
NP as NPC1 is recognized as a key player in cellular recycling [8, 33]. Likewise, it cannot be excluded 
that reduced recycling of the siNGs contributed to the CAD-induced adjuvant effect since ASM 
inhibition is also reported to inhibit vesicle fusion [31]. Altogether, these results suggest that the 
acquired PLD/NPD phenotype as a result of CAD incubation is responsible for the observed 
enhancement of siRNA delivery. 
3.5. The impact of desloratadine incubation time and multiple treatments 
All experiments described above involved a 20 hour CAD treatment. Interestingly, Figure 7A shows 
that both a 2 hour and 20 hour incubation improved siNG-mediated gene silencing to a similar extent. 
Of note, the SSC signal was significantly lower in cells exposed 2 hours to DL as compared to 20 
hours (Figure 7B), which suggests that the increased cellular granularity is only transiently induced. 
Importantly, a 2 hour DL incubation period did not cause any additional cytotoxicity compared to the 
siNGs alone (Figure 7C). These results imply that CADs only trigger minor and transient LMP, 
sufficient to allow improved siRNA release in the cytosol while avoiding lysosomal cell death. This 
non-lethal LMP furthermore suggests that small pores are created in the lysosomal membrane, which 
solely allows uncomplexed siRNA to transfer to the cytosol. Our data corroborate the recent finding 
that sub-lethal concentrations of the apoptotic L-leucyl-L-leucin-methyl ester (LLOMe) transiently 
permeabilize lysosomal membranes followed by fast restoration of lysosomal integrity. Moreover, the 
LLOMe-induced LMP only allowed cytosolic leakage of macromolecules below 10 kDa but not the 
larger apoptosis-evoking cathepsins (20-30 kDa) [34]. Extensive LMP entails the release of lysosomal 
cathepsins as well as cytosolic acidification, leading to uncontrolled cell death. On the other hand, 
also partial LMP might evoke lysosomal cell death in the absence of generalized cytoplasmic 
acidification through the release of cathepsin B and D, which maintain activity at neutral pH. However, 
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in the latter case the action of endogenous cathepsin inhibitors can safeguard cell survival, which 
could in part also explain the lack of cell death upon controlled CAD exposure in our experiments [9, 
35, 36]. Of note, the delivery efficiency of siNGs loaded with the larger 25-27mer Dicer-substrate 
siRNAs (DsiRNA,~18kDa) could also be promoted by sequential CAD incubation (Figure S5), in 
contrast to eGFP-encoding mRNA (~500kDa; Figure S6), implying that higher adjuvant concentrations 
and more extensive LMP might be required for cytosolic delivery of larger nucleic acid therapeutics. 
However, this assumption requires further experimental validation. 
Next, we investigated whether DL treatment influenced the kinetics of the siNG-mediated gene 
silencing. A DL concentration-dependent improvement of initial gene silencing was obtained in 
correspondence to previous results (Figure 7D). From day 2 onwards, the relative eGFP expression 
steadily increased and at day 7 post-transfection eGFP expression again reached basal levels in all 
conditions. Interestingly, confocal images of cells transfected with NGs encapsulating labeled siRNA 
(siGLO green transfection indicator) revealed enlarged siGLO-NG containing vesicles in DL treated 
cells (Figure 7E). This indicates that not all lysosomally accumulated siRNA is released upon a single 
adjuvant treatment, which correlates well with previous reports [10, 11]. Hence, we investigated if 
multiple DL treatments could induce additional siRNA release at later time points, using nuclease 
stabilized siRNA [19, 37]. We observed that upon multiple 2 hour DL treatments, minimal eGFP 
expression levels could be obtained up to 4 days post transfection, compared to negligible gene 
silencing in the absence of DL (Figure 7F). Despite the retained PLD phenotype by DL treatments 
after day 4 (Figure S7), the adjuvant treatments failed to provide further prolongation of the maximal 
gene silencing. This may be attributed to consecutive cell divisions that diluted the siNG-containing 
lysosomes to such an extent that minor additional siRNA release could no longer extend gene 
silencing. 
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Figure 6. CADs induce a phospholipidosis phenotype. (A) Representative confocal images from 
the phospholipid distribution in H1299-WT cells visualized with LipidTOX™ Red PLD detection 
reagent in untreated and desloratadine (DL) or dextrometorphan (DX) treated cells. (B) 
Representative scatter plots from untreated and siNG-transfected cells incubated with 40 µM DL or 30 
µM U18666A. (C) The eGFP silencing induced by adjuvant treatment with 30 µM U18666A compared 
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to siNG transfection alone. (D) Intracellular cholesterol distribution in untreated H1299-WT cells or 
transfected cells treated with DL. (E) Intracellular SM distribution in untreated H1299-WT cells or 
transfected cells additionally treated with 10 µM DL. (F) The percentage eGFP expression in H1299-
eGFP cells following transfection with the siNGs alone or in combination with 300 µM 2OHOA, 10 µM 
DL or the combination of both. Data are represented as the mean ± SEM (n=3) and statistical 
significance is indicated when appropriate (* p<0.05, *** p<0.005). 
3.6. Desloratadine improves therapeutic siRNA delivery 
Finally, we applied our adjuvant strategy to improve delivery of a therapeutic siRNA targeting polo-like 
kinase 1 (PLK1). Reducing PLK1 expression halts the cell cycle and induces apoptosis in p53 
deficient cancer cells, such as the applied H1299 cell line [38, 39]. NGs loaded with control siRNA 
reduced the cell viability to approximately 80% in any condition tested, corroborating previous 
experiments (Figure S8A). The DL adjuvant treatment significantly enhanced siPLK1-mediated 
reduction in cell viability for all siPLK1 doses tested (Figure 7G, Figure S8B), with the combination of 
40 µM DL and 1 nM siPLK1 reaching a comparable effect as 100 nM siPLK1 without adjuvant 
support.  Once again, repeating the adjuvant incubation (2 hours, 40 µM DL) further reduced cell 
viability (Figure 7H).  
This approach requires confirmation in a relevant in vivo model, in which additional challenges like the 
carrier stability, the identification of suitable CAD doses and the selection of a sufficiently predictive in 
vivo model should be taken into account [40, 41]. Importantly, it can be rationalized from the literature 
that this CAD adjuvant approach may likewise enhance siRNA delivery to cancer cells in vivo. Indeed, 
cancer cell lysosomes are generally less stable, show an altered membrane composition and lower 
ASM activity [14, 17, 42]. Of note, therapeutic doses of antidepressant CADs were shown to decrease 
ASM activity in vivo [18]. In addition, CADs were recently reported to induce LMP in cancer cells in 
vivo [14, 17]. Thus, we anticipate that sufficiently high adjuvant concentrations may be reached in 
tissues given the extremely high distribution volumes of CADs and, based on the data presented 
here, non-lethal LMP at lower CAD doses being sufficient to substantially promote siRNA delivery 
[43]. On the other hand, co-encapsulation of the delivery enhancing compound into the nanoparticle 
could further contribute to successful in vivo translation by conferring improved control over extra-and 
intracellular distribution, lowering the required dose or dosing frequency to observe an adjuvant effect 
and reducing systemic toxicity [44]. 
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Figure 7. The lysosomes as a depot for triggered siRNA release. (A-B) The percentage eGFP 
expression and fold change in side scatter (SSC) in H1299-eGFP cells transfected with siNGs alone 
or followed by a 2 hour or 20 hour desloratadine (DL) treatment. (C) Percentage viable cells following 
siNG transfection whether or not combined with 2 hour or 20 hour DL. (D) Kinetics of eGFP 
knockdown in siNG transfected cells followed by 2 hour DL incubation. (E) siGLO signal in H1299-WT 
cells transfected with siGLO-loaded NGs alone or followed by 40 µM DL. (F) Kinetics of eGFP 
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knockdown in cells transfected with siNGs and treated once with 40 µM DL, daily or every other day 
until day six post transfection. (G) Percentage viable H1299-eGFP cells following transfection with 
siPLK1-loaded NGs whether or not subjected to a 2 hour sequential 40 µM DL treatment. (H) Percent 
viable cells after transfection with 1 nM siPLK1-loaded NGs or subjected to one or two 40 µM DL 
treatments. Data are represented as mean ± SEM (n=3) and statistical significance is indicated when 
appropriate by black * when referring to the untreated control and gray * when compared to NG 
transfected cells (* p<0.05, ** p<0.01, *** p<0.005). Finally, statistical significance between the 2 hour 
and 20 hour condition is indicated by the black x (xx p<0.01, xxx p<0.005). (NTC = untreated control, ns 
= not significant) 
 
4. CONCLUSION 
We demonstrated that cationic amphiphilic drugs (CADs) can be repurposed to stimulate functional 
lysosomal escape of siRNA in cancer cells. Indeed, CADs induced the accumulation of phospholipids, 
cholesterol and sphingomyelin, resulting in the enlargement of the lysosomal compartment, the 
induction of lysosomal membrane permeabilization (LMP) and enhanced cytosolic siRNA release. 
Importantly, our results strongly suggest that this acquired lysosomal storage disorder-phenotype and 
concurrent lysosomal destabilization are responsible for the improved siRNA delivery when CADs 
were sequentially applied to NG-transfected cancer cells. As the LMP phenotype is only transiently 
induced, it allows substantial siRNA delivery without affecting cell viability. Remarkably, multiple CAD 
treatments could trigger multiple rounds of siRNA release, highlighting the possibility to exploit 
lysosomes as vesicular depots for the cytosolic delivery of siRNA. 
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